Month: February 2023

Role of Nrf2/HO-1 signaling pathway in treatment of schizophrenia rats with paliperidone was written by Wang, Li;Zhang, Song;Long, Wei. And the article was included in Zhongguo Laonianxue Zazhi in 2022.COA of Formula: C23H27FN4O3 This article mentions the following:

Objective: To investigate the mechanism of NF-E2-related factor (Nrf)2/heme oxygenase (HO)-1 signaling pathway in the treatment of schizophrenia (SZ) rats with paliperidone. Methods: Fifty SPF SD rats were randomly divided into 5 groups: control group (Control group), SZ group (Model group), risperidone group, low-dose paliperidone group and high-dose paliperidone group. The rat model of SZ development was established by i.p. injection of didroxepine maleate (MK-801, 0.25 mg/kg). Rats in low-dose paliperidone group, high-dose paliperidone group and risperidone group were given paliperidone (0.03 mg/kg, once daily), paliperidone (0.30 mg/kg, once daily) and risperidone (0.10), resp. mg/kg, once a day), and rats in Control group and Model group were given the same amount of normal saline. The open field test box was used to analyze the changes of total distance within 10 min in each group. Morris water maze was used to test the reference memory of rats in each group. Social interaction test box was used to test the social interaction ability of rats in each group. And Western blotting was used to detect the expression levels of Caspase-3, Bax protein, Nrf2 and HO-1 in hippocampus tissues of rats in each group. Results: Compared with the Control group, the total distance of spontaneous activity in the Model group was significantly increased, the escape latency was significantly increased, the frequency of crossing the platform was significantly decreased, and the social interaction time and the percentage of non-aggressive behavior were significantly decreased (P<0.05). Compared with the Model group, the total distance of spontaneous activity in risperidone group, the low-dose paliperidone group and the high-dose paliperidone group were significantly decreased, the escape latency was significantly decreased, the number of platform crossing was significantly increased, the social interaction time and the percentage of non-aggressive behavior were significantly increased (P<0.05). Compared with the Control group, the expression levels of caspas-3 and Bax protein in the Model group were significantly increased, and the expression levels of Nrf2 and HO-1 protein were significantly decreased (P<0.05). Compared with the Model group, the protein expression levels of digested caspase-3 and Bax in the hippocampus of risperidone group, low-dose paliperidone group and high-dose paliperidone group were significantly decreased, and the protein expression levels of Nrf2 and HO-1 were significantly increased (P<0.05). Conclusion: Paliperidone can alleviate abnormal behavior in SZ model rats, and may play a role by regulating Nrf2/HO-1 signaling pathway. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4COA of Formula: C23H27FN4O3).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. The weakness of this bond allows the ring opening of these heterocycles under reductive conditions. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.COA of Formula: C23H27FN4O3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data) was written by Mauri, Massimo Carlo;Franco, Gemma;Minutillo, Alessandro;Paletta, Silvia;Di Pace, Chiara;Reggiori, Alessandra;Baldelli, Sara;Cattaneo, Dario. And the article was included in Journal of Clinical Psychopharmacology in 2022.Application of 144598-75-4 This article mentions the following:

The aim of the study was a preliminary evaluation of the maintenance of clin. efficacy and tolerability of paliperidone palmitate in patients with schizophrenia during the transition phase from 1-monthly paliperidone palmitate formulation (PP1M) to PP3M, with the evaluation of plasma levels of the drug. A prospective observational study was conducted for 13 mo involving 22 outpatients, aged 18 to 66 years and clin. stabilized. Patients were affected by schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria. For each patient, clin. assessment, safety and tolerability, and drug plasma level determination were performed. Clin. efficacy was assessed by Brief Psychiatric Rating Scale, Pos. and Neg. Symptom Scale, and Hamilton Rating Scale for Depression. During the first 4 mo of the study, once-monthly paliperidone palmitate was administered, and then during the following 9 mo, the 3-monthly formulation was administered. The time course of the Brief Psychiatric Rating Scale total scores showed a statistically significant (P = 0.006) improvement from T0 to T8; Pos. and Neg. Symptom Scale scores showed a similar time course, with a statistically significant (P = 0.0016) reduction of the mean total score; Hamilton Rating Scale for Depression mean scores showed a statistically significant (P = 0.003) reduction with substantial maintenance of clin. stabilization of the patients. Only 1 patient dropped out after the first PP3M injection. Our preliminary data currently confirm the maintenance of clin. stability shifting from PP1M to PP3M. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Application of 144598-75-4).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazole are described as inhibitors of acetylcholinesterase (AChE). Isoxazole ligands bind to and inhibit the Sxc- antiporter. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Application of 144598-75-4

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Infrared spectra of ion exchanges on polystyrene base was written by Strasheim, A.;Buijs, K.. And the article was included in Spectrochimica Acta in 1961.Name: 5-Methylisoxazole This article mentions the following:

The resins studied were Amberlite IRA-400 and Dowex AG-50. Dispersion media were KBr, petroleum jelly, and hexachlorobutadiene. The spectral range was 700-4000 cm.^-1 The spectrum of a polystyrene film was also obtained for comparison. Vibrational assignments were made for many bands. The functional groups do not all occupy equivalent positions in the resin. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Name: 5-Methylisoxazole).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. An isoxazolyl group is found in many beta-lactamase-resistant antibiotics, such as cloxacillin, dicloxacillin and flucloxacillin. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Name: 5-Methylisoxazole

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Effects of genetic polymorphism in CYP2D6, CYP2C19, and the organic cation transporter OCT1 on amitriptyline pharmacokinetics in healthy volunteers and depressive disorder patients was written by Matthaei, Johannes;Brockmoeller, Juergen;Steimer, Werner;Pischa, Konstanze;Leucht, Stefan;Kullmann, Maria;Jensen, Ole;Ouethy, Typhaine;Tzvetkov, Mladen Vassilev;Rafehi, Muhammad. And the article was included in Frontiers in Pharmacology in 2021.Synthetic Route of C23H27FN4O3 This article mentions the following:

The tricyclic antidepressant amitriptyline is frequently prescribed but its use is limited by its narrow therapeutic range and large variation in pharmacokinetics. Apart from interindividual differences in the activity of the metabolizing enzymes cytochrome P 450 (CYP) 2D6 and 2C19, genetic polymorphism of the hepatic influx transporter organic cation transporter 1 (OCT1) could be contributing to interindividual variation in pharmacokinetics. Here, the impact of OCT1 genetic variation on the pharmacokinetics of amitriptyline and its active metabolite nortriptyline was studied in vitro as well as in healthy volunteers and in depressive disorder patients. Amitriptyline and nortriptyline were found to inhibit OCT1 in recombinant cells with IC₅₀ values of 28.6 and 40.4μM. Thirty other antidepressant and neuroleptic drugs were also found to be moderate to strong OCT1 inhibitors with IC₅₀ values in the micromolar range. However, in 35 healthy volunteers, preselected for their OCT1 genotypes, who received a single dose of 25 mg amitriptyline, no significant effects on amitriptyline and nortriptyline pharmacokinetics could be attributed to OCT1 genetic polymorphism. In contrast, the strong impact of the CYP2D6 genotype on amitriptyline and nortriptyline pharmacokinetics and of the CYP2C19 genotype on nortriptyline was confirmed. In addition, acylcarnitine derivatives were measured as endogenous biomarkers for OCT1 activity. The mean plasma concentrations of isobutyrylcarnitine and 2-methylbutyrylcarnitine were higher in participants with two active OCT1 alleles compared to those with zero OCT1 activity, further supporting their role as endogenous in vivo biomarkers for OCT1 activity. A moderate reduction in plasma isobutyrylcarnitine concentrations occurred at the time points at which amitriptyline plasma concentrations were the highest. In a second, independent study sample of 50 patients who underwent amitriptyline therapy of 75 mg twice daily, a significant trend of increasing amitriptyline plasma concentrations with decreasing OCT1 activity was observed (p = 0.018), while nortriptyline plasma concentrations were unaffected by the OCT1 genotype. Altogether, this comprehensive study showed that OCT1 activity does not appear to be a major factor determining amitriptyline and nortriptyline pharmacokinetics and that hepatic uptake occurs mainly through other mechanisms. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Synthetic Route of C23H27FN4O3).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Fe(CO)5 efficiently cleaves the N–O bond of fused isoxazolo-1,4-quinones to give the corresponding imines.All the common reducing reagents failed to open the isoxazole ring.Synthetic Route of C23H27FN4O3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Synthesis of some polyheterocyclic systems with isolated nuclei was written by Martin, Nazario;Quinteiro, Margarita;Seoane, Carlos;Soto, Jose L.. And the article was included in Revista de la Real Academia de Ciencias Exactas, Fisicas y Naturales de Madrid in 1987.Safety of 5-Methylisoxazole This article mentions the following:

Knoevenagel-type condensation reactions of heterocyclic aldehydes were carried out. Thus, treatment of RCHO (R = pyridyl, pyrrolyl, furyl, etc.) with active methylene compounds PhCOCH₂R¹ (R¹ = CN, CO₂Et) in EtOH containing piperidine afforded benzoylheteroarylacrylonitrile and -acrylates RCH:CR¹COPh (I). The I underwent cyclization with malononitrile to give 4H-pyrans II. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6Safety of 5-Methylisoxazole).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives. Isoxazole are described as inhibitors of acetylcholinesterase (AChE). Isoxazole ligands bind to and inhibit the Sxc- antiporter. Isoxazole can be synthesised via a variety of methods. Examples include via the reaction of hydroxylamine with 1,3-diketones or derivatives of propiolic acid.Safety of 5-Methylisoxazole

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Tailoring lipid nanoconstructs for the oral delivery of paliperidone: Formulation, optimization and in vitro evaluation was written by Rehman, Saleha;Nabi, Bushra;Baboota, Sanjula;Ali, Javed. And the article was included in Chemistry and Physics of Lipids in 2021.Electric Literature of C23H27FN4O3 This article mentions the following:

The present research work involves Quality by Design (QbD)-based fabrication of lipid nanoconstructs (LNC) of paliperidone (PPD) bearing superior biopharmaceutical attributes. LNC of paliperidone was prepared by melt emulsification-probe sonication and high-pressure homogenization method followed by optimization using QbD approach. Preparing LNC by both these methods will give the benefit of identifying the best optimized formulation which will be further evaluated for in vitro studies. The best optimized formulation was obtained using melt emulsification-probe sonication technique with small particle size (86.35 nm), high entrapment efficiency (90.07%), and high loading capacity (8.49%). The drug release from LNC was found to be 5, 8, and 9-folds greater than drug suspension in pH 1.2, 6.8, and 7.4 resp. (p < 0.001). Stability studies of LNC in simulated gastric fluid pH 1.2 and fasted state simulated intestinal fluid depicted no alteration in particle size and polydispersity index of LNC but were found to increase in fed state simulated intestinal fluid. The drug permeability through rat intestine for LNC was found to be approx. 6-folds (p < 0.05) greater as compared to the drug suspension which was further confirmed by confocal microscopy. The in vitro lipolysis study presented significantly highest solubilization (p < 0.001) in the aqueous phase thereby anticipating higher in vivo absorption. Thus, it was concluded that LNC bears the knack of improving the solubilization and permeation potential of an otherwise hydrophobic drug, paliperidone. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Electric Literature of C23H27FN4O3).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. An isoxazolyl group is found in many beta-lactamase-resistant antibiotics, such as cloxacillin, dicloxacillin and flucloxacillin. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Electric Literature of C23H27FN4O3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Enthalpies of combustion and formation of 3-methylisoxazole and 5-methylisoxazole was written by Hamilton, Walter S.;Benton, Susan;French, Jennifer;McCormick, Deborah;Pustejovsky, Sharon;Thompson, Patricia. And the article was included in Journal of Chemical and Engineering Data in 1978.HPLC of Formula: 5765-44-6 This article mentions the following:

The enthalpies of combustion of 3-methylisoxazole [30842-90-1] and 5-methylisoxazole [5765-44-6] were measured by precision O-bomb calorimetry. The following values, based on the mass of sample burned, are reported for the standard enthalpy of combustion, ΔH°_c (298.15 K)/kcal_th mol^-1, of these compounds in the liquid state: 3-methylisoxazole, -546.00 ± 0.14; 5-methylisoxazole, -545.65 ± 0.17. Enthalpies of vaporization, determined calorimetrically, are 3-methylisoxazole, 9.51 ± 0.05 kcal mol^-1, and 5-methylisoxazole, 9.48 ± 0.04 kcal mol^-1. These data were used to calculate standard enthalpies of formation for the gaseous compounds, ΔH°_f(g), which are 3-methylisoxazole, 8.52 ± 0.16 kcal mol^-1, and 5-methylisoxazole, 8.14 ± 0.18 kcal mol^-1. Throughout this paper cal_th = 4.184 J and atm = 101.325 kPa. In the experiment, the researchers used many compounds, for example, 5-Methylisoxazole (cas: 5765-44-6HPLC of Formula: 5765-44-6).

5-Methylisoxazole (cas: 5765-44-6) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. The most common methods for N–O bond cleavage in isoxazoles are hydrogenation with palladium or platinum catalysts or with Raney Ni. Recent developments have shown that Mo(CO)6 efficiently cleaves the N–O bond in isoxazoles.HPLC of Formula: 5765-44-6

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Targeting the von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction was written by Buckley, Dennis L.;Van Molle, Inge;Gareiss, Peter C.;Tae, Hyun Seop;Michel, Julien;Noblin, Devin J.;Jorgensen, William L.;Ciulli, Alessio;Crews, Craig M.. And the article was included in Journal of the American Chemical Society in 2012.Product Details of 19668-85-0 This article mentions the following:

E3 ubiquitin ligases, which bind protein targets, leading to their ubiquitination and subsequent degradation, are attractive drug targets due to their exquisite substrate specificity. However, the development of small-mol. inhibitors has proven extraordinarily challenging as modulation of E3 ligase activities requires the targeting of protein-protein interactions. Using rational design, we have generated the first small mol. targeting the von Hippel-Lindau protein (VHL), the substrate recognition subunit of an E3 ligase, and an important target in cancer, chronic anemia, and ischemia. We have also obtained the crystal structure of VHL bound to our most potent inhibitor, confirming that the compound mimics the binding mode of the transcription factor HIF-1α, a substrate of VHL. These results have the potential to guide future development of improved lead compounds as therapeutics for the treatment of chronic anemia and ischemia. In the experiment, the researchers used many compounds, for example, 3-Methylisoxazole-5-acetic Acid (cas: 19668-85-0Product Details of 19668-85-0).

3-Methylisoxazole-5-acetic Acid (cas: 19668-85-0) belongs to isoxazole derivatives. Isoxazole rings are found in some natural products, such as ibotenic acid and muscimol. Some alternative routes for the synthesis of isoxazoles have also been developed and reported. The 2-benzoyl-2-halo-2H-azirines provide 4-haloisoxazoles in good yields after heating in toluene at reflux temperature.Product Details of 19668-85-0

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms was written by Chen, Natalie Cheng;Borthakur, Gautam;Pemmaraju, Naveen. And the article was included in Leukemia & Lymphoma in 2021.Application In Synthesis of (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide This article mentions the following:

With improved understanding of the epigenetic alterations underlying cancer development, numerous novel agents targeting pathways involved in epigenetic modifications and transcription including bromodomain inhibitors are under active investigation. We aim to discuss epigenetic modulation with a focus on bromodomain extra-terminal inhibitors (BETi) in the treatment of myeloid neoplasms. Since the first proof-of-concept description of BETi synthesis and its antineoplastic effect, approx. 20 BETi have been generated and many of them are studied in the context of cancer treatment. Emerging pre-clin. and early clin. studies suggest that BETi may have activity in the management of many hematol. malignancies including acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), myeloproliferative neoplasm (MPNs), and lymphoma. We comprehensively reviewed and summarized preclin. and clin. data on BETi in treating myeloid neoplasms. In the experiment, the researchers used many compounds, for example, (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide (cas: 1380087-89-7Application In Synthesis of (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide).

(S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide (cas: 1380087-89-7) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. Some alternative routes for the synthesis of isoxazoles have also been developed and reported. The 2-benzoyl-2-halo-2H-azirines provide 4-haloisoxazoles in good yields after heating in toluene at reflux temperature.Application In Synthesis of (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample was written by Schoretsanitis, Georgios;Haen, Ekkehard;Conca, Andreas;Piacentino, Daria;Ridders, Florian;Hiemke, Christoph;Grunder, Gerhard;Paulzen, Michael. And the article was included in Pharmacopsychiatry in 2021.Synthetic Route of C23H27FN4O3 This article mentions the following:

IntroductionMajor smoking effects have been reported for a series of psychotropic agents, mainly including substrates of CYP450 1A2, although smoking may also affect alternative metabolic pathways. To our knowledge, smoking effects on paliperidone pharmacokinetics have not been assessed yet. MethodsWe compared plasma concentrations of paliperidone as well as dose-corrected-plasma concentrations (C/D) from a naturalistic database between smokers and nonsmokers using nonparametrical tests, such as the Mann-Whitney U-test (MWU). Addnl., we compared light and heavy smokers with nonsmokers sep. ResultsComparing 55 smokers with 37 nonsmokers treated with oral paliperidone, no differences in the percentage of females, age, body weight, body mass index, and daily paliperidone dose were reported (p=0.709 for χ ², p=0.26, p=0.38, p=0.67, and p=0.8 for MWU). No differences were detected in plasma concentrations or C/D values (p=0.50 and p=0.96 for MWU). Likewise, differences in daily dose, plasma concentrations, or C/D values were not significant between light smokers (n=17) and nonsmokers (p=0.61, p=0.81, and p=0.33 for MWU) or heavy smokers (n=22) and nonsmokers (p=0.874, p=0.38, and p=0.59; MWU in all cases). DiscussionPaliperidone is not affected by smoking, and paliperidone dose-adjustments in smokers may not be necessary. This may be seen as an essential difference to risperidone, whose cytochrome-mediated metabolism might be affected by smoking. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Synthetic Route of C23H27FN4O3).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazole are described as inhibitors of acetylcholinesterase (AChE). Isoxazole ligands bind to and inhibit the Sxc- antiporter. Some alternative routes for the synthesis of isoxazoles have also been developed and reported. The 2-benzoyl-2-halo-2H-azirines provide 4-haloisoxazoles in good yields after heating in toluene at reflux temperature.Synthetic Route of C23H27FN4O3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem